Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. MarketScreener Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. AstraZeneca PLC
  6. News
  7. Summary
    AZN   GB0009895292

ASTRAZENECA PLC

(AZN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

AstraZeneca Covid-19 Vaccine Restrictions Pile Up, Complicating Shot Roll Outs

04/08/2021 | 11:18am EDT

By Rhiannon Hoyle and Giovanni Legorano

Australia, Belgium, Italy and Spain joined the U.K. and several other European nations in restricting the rollout of AstraZeneca PLC's Covid-19 vaccine, a day after European regulators said there may be a link between the vaccine and rare, but sometimes deadly blood clotting.

The restrictions deal separate blows to several national vaccine rollouts that had already been hampered by supply constraints and other delays.

Australia's immunization advisory body said Thursday that the AstraZeneca shot should preferably not be given to people under 50. The country has been betting heavily on locally made, AstraZeneca-developed shots. Australian officials said they would need to review their vaccine purchases and that the advice might delay how soon first doses can be offered to all Australians.

"It is an abundance of caution, and it's a caution that has been exercised consistent with many other countries around the world, and we would expect to see that also continue in other countries now making similar decisions," said Prime Minister Scott Morrison.

Italy and Spain both said they would recommend the shot only for those over 60. Belgium set the bar at over the age of 55.

The recommendations followed advice in the U.K. on Wednesday restricting the AstraZeneca vaccine for people under 30, citing concerns that it may cause potentially deadly blood clots in very rare instances. The same day, the European Union's top medicines regulator said there may be a link between the shot and the rare blood clotting, although it didn't recommend any age restrictions for the shot. It said it continues to believe the benefits of the shot outweigh any risks.

AstraZeneca said both the U.K. and EU review "reaffirmed the vaccine offers a high-level of protection against all severities of Covid-19 and that these benefits continue to far outweigh the risks." It said it was working with regulators to change product information and working to understand "individual cases, epidemiology and possible mechanisms that could explain these extremely rare events."

Brendan Murphy, secretary of Australia's health department, said Australia would still have a big need for the AstraZeneca shot. "It is going to be a really important vaccine to vaccinate a significant proportion of the population," he said.

The German government, meanwhile, has already been recommending the AstraZeneca vaccine only be used in people age 60 and older. Anyone under that age can still get the vaccine if they want it, but at their own risk and after being informed about possible complications by a qualified health professional.

In most regions of Germany, eligible vaccine recipients include only those over 70 and people with chronic conditions such as asthma. Until recently, the small number of people who are eligible for any vaccine under Germany's strict prioritization system had been shunning AstraZeneca's shot, leading unused doses to pile up in the country's vaccination centers.

But there is still demand for the vaccine among younger and less vulnerable Germans. Confronted with the stockpile of shots, several states have allowed anyone over 60 to book an appointment for the unused AstraZeneca vaccines. Doses were snapped up within days.

Denmark suspended AstraZeneca vaccinations for anyone until later this month and is currently reviewing findings about possible complications. Norway has also stopped using the shot until at least April 15. Pending a review of the European Medicines Agency's latest advice on AstraZeneca, Sweden said it would continue to give the vaccine only to those over 65. Late last month, Canadian authorities recommended a halt on administering the AstraZeneca vaccine to people under the age of 55.

(END) Dow Jones Newswires

04-08-21 1318ET

All news about ASTRAZENECA PLC
04/16ASTRAZENECA  : Quebec to deploy sound trucks in Montreal to announce mobile vacc..
AQ
04/16ASTRAZENECA  : Doctors say lowering age cutoff for AstraZeneca vaccine makes sen..
AQ
04/16Consumer Cos Climb On Reopening Optimism -- Consumer Roundup
DJ
04/16Health Care Up After Strong Start to Earnings Season -- Health Care Roundup
DJ
04/16Vaccine Manufacturing Issues Force Moderna to Cut Supplies to Canada, U.K.
DJ
04/16No Causal Link Found So Far Between J&J's Covid-19 Vaccine and Blood-Clot Cas..
DJ
04/16ASTRAZENECA  : German's IDT to make 10M AstraZeneca vaccine doses in 2021
AQ
04/16ASTRAZENECA  : Covid-19 - Lagos, Kano Lead As Nigeria Vaccinates Over 1m Persons
AQ
04/16MARKET CHATTER : Johnson & Johnson Reportedly Asked Other COVID-19 Vaccine Produ..
MT
04/16ASTRAZENECA  : Australia's Medicine Watchdog Links Woman's Death To AstraZeneca ..
MT
More news
Financials (USD)
Sales 2021 30 805 M - -
Net income 2021 5 064 M - -
Net Debt 2021 11 692 M - -
P/E ratio 2021 26,1x
Yield 2021 2,79%
Capitalization 134 B 134 B -
EV / Sales 2021 4,73x
EV / Sales 2022 4,09x
Nbr of Employees 76 100
Free-Float 95,8%
Chart ASTRAZENECA PLC
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 25
Average target price 129,60 $
Last Close Price 102,07 $
Spread / Highest target 62,6%
Spread / Average Target 27,0%
Spread / Lowest Target -7,74%
EPS Revisions
Managers and Directors
NameTitle
Pascal Soriot Chief Executive Officer & Executive Director
Marc Pierre Jean Dunoyer Chief Financial Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Menelas N. Pangalos EVP-Biopharmaceuticals Research & Development
Pam P. Cheng Executive VP-Operations & Information Technology
Sector and Competitors
1st jan.Capitalization (M$)
ASTRAZENECA PLC0.76%133 897
JOHNSON & JOHNSON3.09%422 260
ROCHE HOLDING AG0.16%289 178
PFIZER INC.2.15%209 739
NOVARTIS AG-3.73%197 072
MERCK & CO., INC.-5.29%194 049